Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 24 of 295 for:    IFNA2 AND PEG-interferon alfa-2b

SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) vs. INTRON®A (SCH 30500, MK-2958) as Adjuvant Therapy for Melanoma (C98-135, MK-4031-002)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03552549
Recruitment Status : Terminated (This study was closed to enrollment prematurely due to sub-optimal accrual.)
First Posted : June 12, 2018
Results First Posted : July 24, 2019
Last Update Posted : July 24, 2019
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

Tracking Information
First Submitted Date  ICMJE May 29, 2018
First Posted Date  ICMJE June 12, 2018
Results First Submitted Date  ICMJE March 29, 2019
Results First Posted Date  ICMJE July 24, 2019
Last Update Posted Date July 24, 2019
Actual Study Start Date  ICMJE August 5, 1998
Actual Primary Completion Date February 19, 2001   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: July 16, 2019)
Progression-free Survival (PFS) [ Time Frame: From time of randomization to time of progression or death (up to approximately 26 months) ]
Progression-free survival time was defined as the time from the date of randomization to the date of disease progression or the date of death regardless of the cause. PFS was to be assessed by clinical observation, with recurrence documented by appropriate radiographic and histologic methods, and confirmed by Independent Central Review.
Original Primary Outcome Measures  ICMJE
 (submitted: May 29, 2018)
Progression-free Survival Time [ Time Frame: From time of randomization to time of progression or death (up to 2 years) ]
Change History Complete list of historical versions of study NCT03552549 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: July 16, 2019)
Overall Survival [ Time Frame: From time of randomization to time of death (up to approximately 26 months) ]
Overall survival (OS) is the time from randomization to death due to any cause. Participants were to be followed for survival every 3 months. Participants without documented death at the time of the final analysis were to be censored at the date of the last follow-up. After the early termination of the study, participants were followed for safety only. Although the OS analysis is not in the clinical study report due to early termination of the study, an OS ad hoc analysis was requested by the FDA and is therefore presented in this outcome measure. Below table presents the median duration of survival for participants.
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) vs. INTRON®A (SCH 30500, MK-2958) as Adjuvant Therapy for Melanoma (C98-135, MK-4031-002)
Official Title  ICMJE A Randomized Phase II/III Trial of SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron) vs. INTRON®A as Adjuvant Therapy for Melanoma
Brief Summary This is a Phase II/III randomized, controlled, multicenter, open-label study designed to assess the safety, efficacy, and impact on quality of life of PEG Intron (MK-4031) and INTRON® A (MK-2958) and the pharmacokinetics of PEG Intron when given as adjuvant (after surgery) therapy in participants with resected (surgically removed) Stage III node-positive cutaneous melanoma.
Detailed Description This study was closed to enrollment prematurely due to sub-optimal accrual. Participants who were enrolled prior to enrollment closure were allowed to continue to receive study drug; these participants were followed for safety only.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Melanoma
Intervention  ICMJE
  • Biological: PEG-Intron
    Polyethylene glycol (PEG)12000 Interferon alfa 2-b subcutaneous injection.
    Other Name: peginterferon alfa-2b, SCH 54031, MK-4031
  • Biological: INTRON A
    Interferon alfa-2b, recombinant for intravenous injection.
    Other Name: interferon alfa-2b, SCH 30500, MK-2958
Study Arms  ICMJE
  • Experimental: PEG-Intron
    Participants with stage III node positive cutaneous melanoma will receive subcutaneous PEG-Intron (6.0 ug/kg weekly) for 2 years post-surgery.
    Intervention: Biological: PEG-Intron
  • Experimental: INTRON A
    Participants with stage III node positive cutaneous melanoma will receive intravenous INTRON A (20 million international units [MIU]/m^2/day, 5 days a week) for 4 weeks followed by subcutaneous INTRON A (10 MIU/m^2 three times per week) for 48 weeks post-surgery.
    Intervention: Biological: INTRON A
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: May 29, 2018)
126
Original Actual Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE February 19, 2001
Actual Primary Completion Date February 19, 2001   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Participants must have histologically documented primary cutaneous melanoma meeting one of the following staging criteria:

    • Primary melanoma of any stage in the presence of N1 regional lymph node metastases detected at elective lymph node dissection or sentinel node biopsy, with clinically inapparent regional lymph node metastasis (any pTN1M0).
    • Clinically apparent N1 or N2a regional lymph node involvement synchronous with primary melanoma of T1-4 (any pTN1-2aM0).
    • Regional lymph node recurrence at any interval after appropriate surgery for primary melanoma of any depth (any primary tumor [pT], r N1-2a M0).
  • Participants must have had all known disease completely resected with adequate surgical margins within 56 days prior to randomization into the study
  • Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Participants must have adequate hepatic, renal and bone marrow function as defined by the following parameters obtained within 14 days prior to initiation of study treatment:

    • Hematology: white blood cells (WBC) ≥3,000 cells/µL and hemoglobin ≥9 g/dL.
    • Renal and hepatic function: serum creatinine <2.0 mg/dL; aspartate aminotransferase (AST or SGOT) and alanine aminotransferase (ALT or SGPT) <2 times upper limit of laboratory normal (ULN); and serum bilirubin <2 times ULN
  • Participants must sign and date a voluntary informed consent form before study entry, be willing to participate in this study and agree to complete all follow-up assessments.

Exclusion Criteria:

  • Participants who have received any prior chemotherapy, immunotherapy hormonal or radiation therapy for melanoma.
  • Participants who have evidence of distant or non-regional lymph node metastases, in-transit metastases, or positive lymph nodes with an unknown primary.
  • Participants whose disease cannot be completely surgically resected because of gross extracapsular extension.
  • Participants who have previously received interferon for any reason.
  • Participants who have severe cardiovascular disease, i.e., arrhythmias requiring chronic treatment, congestive heart failure (New York Heart Association [NYHA] Class III or IV) or symptomatic ischemic heart disease.
  • Participants who have a history of neuropsychiatric disorder requiring hospitalization.
  • Participants with thyroid dysfunction not responsive to therapy.
  • Participants with uncontrolled diabetes mellitus.
  • Participants with a history of prior malignancy within the past 5 years other than surgically cured non-melanoma skin cancer or cervical carcinoma in situ.
  • Participants who have a history of seropositivity for human immunodeficiency virus (HIV).
  • Participants who are pregnant, lactating, or of reproductive potential and not practicing an effective means of contraception.
  • Participants with active and/or uncontrolled infection, including active hepatitis.
  • Participants with a medical condition requiring chronic systemic corticosteroids.
  • Participants who are known to be actively abusing alcohol or drugs.
  • Participants who have received any experimental therapy within 30 days prior to randomization in this study.
  • Participants who have not recovered from the effects of recent surgery.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 70 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03552549
Other Study ID Numbers  ICMJE C98135
MK-4031-002 ( Other Identifier: Merck Protocol Number )
C98-135 ( Other Identifier: Schering-Plough Protocol Number )
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Merck Sharp & Dohme Corp.
Study Sponsor  ICMJE Merck Sharp & Dohme Corp.
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Medical Director Merck Sharp & Dohme Corp.
PRS Account Merck Sharp & Dohme Corp.
Verification Date July 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP